newsweb.no
Utsteder
Utst.ID
Instrument
  Nullstill...
Kategori
Fra dato
Til dato
Skjul ikke-informasjonspliktige pressemeldinger Info...
Vis kun lagringspliktige meldinger Info...
Vis kun siste versjon av melding Info...
Vis kun aktive utstedere Info...
Vis kun Oslo Børs meldinger Info...
 
MeldingsID: 298581
Dato/tid 15.02.2012 08:45
Utsteder Algeta ASA
UtstederID ALGETA
Instrument
Marked OB
Kategori KAPITALENDRINGER / UTBYTTEOPPLYSNINGER
Informasjonspliktig   Informasjonspliktige opplysninger   Lagringspliktig melding
Vedlegg
Tittel Algeta ASA announces that the bookbuilding is completed - 3 million shares priced at NOK 143.0
Tekst


NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN
                                 OR AUSTRALIA.

          Ikke for distribusjon i USA, Canada, Japan eller Australia.

Oslo, 15 February 2012:
Algeta ASA (Ticker: ALGETA) (the "Company") announces the successful completion
of the bookbuilding period for the private placement of 3,000,000 shares,
consisting of 2,000,000 new shares and a secondary offering of 1,000,000
existing shares by funds managed by Abingworth (the "Offering"). In summary:

  * The bookbuilding period commenced on 13 February 2012 and ended on 15
    February at 08:30 CET
  * Following the completion of the bookbuilding, a total number of 2,000,000
    new shares and 1,000,000 existing shares have been allotted to investors in
    the Offering
  * The Company will have outstanding 42,463,921 shares after completion of the
    Offering
  * The Offer Shares, par value NOK 0,50 each, have been priced at NOK 143.0 per
    share
  * The Offering will raise net proceeds to the Company of approximately NOK
    260 million (~ USD 45 million)
  * The Offer Shares will be delivered to investors in the VPS, expected to take
    place on or about 20 February 2012
  * Notifications of allotted shares and the corresponding amount to be paid by
    investors are expected to be made by the Managers on 15 February 2012
  * Subsequent to and separately from the Offering, the Company has resolved to
    conduct a repair offering (the "Repair Offering") of up to 650,000 shares
    determined on the basis of the allocation of Offer Shares to existing
    shareholders in the Offering relative to their proportionate shareholding,
    at NOK 143.0 per share. The Repair Offering will be directed only towards
    existing shareholders of the Company as of 13 February 2012, holding 50,000
    shares or less, who did not participate in the Offering and who are not
    resident in a jurisdiction where such offering would be unlawful. The Repair
    Offering will be made in a separate prospectus to be approved by the
    Financial Supervisory Authority of Norway, and the Repair Offering is
    expected to be completed in March 2012. The board of the Company will
    resolve the final number of shares to be offered in the Repair Offering
    prior to the opening of trading on Oslo Børs on 17 February 2012.


For further information about the Offering, reference is made to the prospectus
for the Offering dated 13 February 2012 which is available to qualified
investors on the Company's website, www.algeta.com, and at the offices of the
Company and the Managers.

                                      ###


For further information, please contact



 Mike Booth                           +47 2202 4510

 Communications & Corporate Affairs   ir@algeta.com



 International media enquiries:       +44 207 638 9571

 Mark Swallow                         mark.swallow@citigatedr.co.uk

 Citigate Dewe Rogerson









About Algeta

Algeta is a company focused on developing novel targeted therapies for patients
with cancer based on its alpha-pharmaceutical platform.

Algeta's lead product Alpharadin (radium-223 chloride) is in development as a
potential new treatment for cancer patients with bone metastases. It is in pre-
registration for castration-resistant prostate cancer (CRPC) patients with bone
metastases, and filings are expected mid 2012 in the USA and Europe; Alpharadin
has Fast Track designation for this indication in the USA.

Alpharadin is also under clinical investigation in breast cancer patients with
bone metastases and in combination with docetaxel chemotherapy in CPRC patients
with bone metastases.

Alpharadin is being developed and will be commercialized, pending approval,
under a global agreement with Bayer Pharma AG.

Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs),
which are based on conjugating the alpha-emitter thorium-227 to targeting
molecules, as a basis of a future pipeline of tumor-targeting alpha-
pharmaceutical candidates.

The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock
Exchange (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.


US Legend

These materials are not and do not form part of an offer of or solicitation to
purchase or subscribe securities in the United States. The securities to which
these materials relate have not been registered under the U.S. Securities Act of
1933 (the "Securities Act") or

under the securities legislation of any state of the United States, and may not
be offered or sold in the United States absent registration under or pursuant to
an exemption from, or in a transaction not subject to, the registration
requirements under the Securities Act. There will be no public offering of the
securities in the United States.

UK Legend

This document is only being distributed to and is only directed at (i) persons
who are outside the United Kingdom or (ii) to investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other
persons to whom it may lawfully be communicated, falling within Article
49(2)(a) to (d) of the Order (all such persons together being referred to as
"relevant persons"). The securities are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such securities
will be engaged in only with, relevant persons. Any person who is not a relevant
person should not act or rely on this document or any of its contents.

Forward-looking Statements

This news release contains certain forward-looking statements based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. Such forward-looking
statements reflect our current views and are based on the information currently
available to Algeta. Algeta cannot give any assurance to the correctness of such
statements. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied by these
forward-looking statements. These factors include, among other things, risks or
uncertainties associated with the success of future clinical trials,
collaborations with other companies in the development of targeting molecules
and alpha particle payloads, risks associated with technological development,
growth management, general economic and business conditions and the pricing
environment, the impact of competition, the ability to successfully
commercialize Alpharadin and our other products, the risk that research &
development will not yield new products that achieve commercial success,
manufacturing capacity, the risk of non-approval of patents not yet granted,
risks in obtaining regulatory approvals for Alpharadin and our other products
and difficulties of obtaining relevant governmental approvals for new products,
and the other risks and uncertainties described in our annual report.



[HUG#1585848] 
    

Les om ansvar og rettigheter.